These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 37887199)

  • 1. The Clinical Efficacy of Multidose Oritavancin: A Systematic Review.
    Baiardi G; Cameran Caviglia M; Piras F; Sacco F; Prinapori R; Cristina ML; Mattioli F; Sartini M; Pontali E
    Antibiotics (Basel); 2023 Sep; 12(10):. PubMed ID: 37887199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The CHROME Study, a Real-world Experience of Single- and Multiple-Dose Oritavancin for Treatment of Gram-Positive Infections.
    Redell M; Sierra-Hoffman M; Assi M; Bochan M; Chansolme D; Gandhi A; Sheridan K; Soosaipillai I; Walsh T; Massey J
    Open Forum Infect Dis; 2019 Nov; 6(11):ofz479. PubMed ID: 31844635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study.
    Corey GR; Good S; Jiang H; Moeck G; Wikler M; Green S; Manos P; Keech R; Singh R; Heller B; Bubnova N; O'Riordan W;
    Clin Infect Dis; 2015 Jan; 60(2):254-62. PubMed ID: 25294250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of oritavancin for the treatment of acute bacterial skin and skin-structure infections: a systematic review and meta-analysis.
    Zhang H; Zhou W; Wang J; Cai Y
    J Glob Antimicrob Resist; 2021 Jun; 25():380-389. PubMed ID: 33989846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of chronic osteomyelitis with multidose oritavancin: A case series and literature review.
    Chastain DB; Davis A
    Int J Antimicrob Agents; 2019 Apr; 53(4):429-434. PubMed ID: 30537532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Acute Osteomyelitis with Once-Weekly Oritavancin: A Two-Year, Multicenter, Retrospective Study.
    Van Hise NW; Chundi V; Didwania V; Anderson M; McKinsey D; Roig I; Sharma A; Petrak RM
    Drugs Real World Outcomes; 2020 Jun; 7(Suppl 1):41-45. PubMed ID: 32588385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies.
    Corey GR; Loutit J; Moeck G; Wikler M; Dudley MN; O'Riordan W;
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29358292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Real-world Patient Registry for Oritavancin Demonstrates Efficacy and Safety Consistent With the Phase 3 SOLO Program.
    Redell M; Moeck G; Lucasti C; Durso S; Kennedy C; Fusaro K; Loutit J; Dudley M
    Open Forum Infect Dis; 2018 Jun; 5(6):ofy051. PubMed ID: 29977954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oritavancin: A Novel Lipoglycopeptide.
    Mattox J; Belliveau P; Durand C
    Consult Pharm; 2016 Feb; 31(2):86-95. PubMed ID: 26842686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial.
    Dunbar LM; Milata J; McClure T; Wasilewski MM;
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3476-84. PubMed ID: 21537018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oritavancin for acute bacterial skin and skin structure infections.
    Messina JA; Fowler VG; Corey GR
    Expert Opin Pharmacother; 2015 May; 16(7):1091-8. PubMed ID: 25803197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Oritavancin Relative to Vancomycin for Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Outpatient Setting: Results From the SOLO Clinical Trials.
    Lodise TP; Redell M; Armstrong SO; Sulham KA; Corey GR
    Open Forum Infect Dis; 2017; 4(1):ofw274. PubMed ID: 28480266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections.
    Brade KD; Rybak JM; Rybak MJ
    Infect Dis Ther; 2016 Mar; 5(1):1-15. PubMed ID: 26831328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014.
    Biedenbach DJ; Arhin FF; Moeck G; Lynch TF; Sahm DF
    Int J Antimicrob Agents; 2015 Dec; 46(6):674-81. PubMed ID: 26541881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus.
    Corey GR; Arhin FF; Wikler MA; Sahm DF; Kreiswirth BN; Mediavilla JR; Good S; Fiset C; Jiang H; Moeck G; Kabler H; Green S; O'Riordan W;
    Int J Antimicrob Agents; 2016 Nov; 48(5):528-534. PubMed ID: 27665522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oritavancin: A Long-Half-Life Lipoglycopeptide.
    Saravolatz LD; Stein GE
    Clin Infect Dis; 2015 Aug; 61(4):627-32. PubMed ID: 25900171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oritavancin - a new semisynthetic lipoglycopeptide agent to tackle the challenge of resistant gram positive pathogens.
    Das B; Sarkar C; Schachter J
    Pak J Pharm Sci; 2013 Sep; 26(5):1045-55. PubMed ID: 24035967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-dose oritavancin in the treatment of acute bacterial skin infections.
    Corey GR; Kabler H; Mehra P; Gupta S; Overcash JS; Porwal A; Giordano P; Lucasti C; Perez A; Good S; Jiang H; Moeck G; O'Riordan W;
    N Engl J Med; 2014 Jun; 370(23):2180-90. PubMed ID: 24897083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Outcomes and Economic Impact of Oritavancin for Gram-Positive Infections: A Single Academic Medical Center Health System Experience.
    Brownell LE; Adamsick ML; McCreary EK; Vanderloo JP; Ernst EJ; Jackson ER; Schulz LT
    Drugs Real World Outcomes; 2020 Jun; 7(Suppl 1):13-19. PubMed ID: 32592120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.